Trials of aducanumab in Alzheimer disease were previously discontinued following a phase III futility analysis, but Biogen now says that additional data indicate that longer exposure to the higher dose might be effective. The company is seeking FDA approval for the treatment; however, the limited data released do not establish efficacy.

中文翻译：

---

随着 Biogen 声称 aducanumab 的转变，问题出现了。

在 III 期无效分析后，aducanumab 在阿尔茨海默病中的试验先前已停止，但百健（Biogen）现在表示，更多数据表明，更长时间暴露于更高剂量可能是有效的。该公司正在寻求 FDA 对该治疗的批准；然而，发布的有限数据并不能确定疗效。